Safety, Side Effects and Patient Acceptance of the Luteinizing Hormone Releasing Hormone Agonist Leuprolide in Treatment of Benign Prostatic Hyperplasia

Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men

“…This gender differences in erythropoiesis have been traditionally ascribed to the amount of androgens that is greater in men than in women, but they could be also related to menstrual blood loss in women [10], even though evidence on this latter mechanism are controversial [11]. Furthermore, the androgen deprivation in men reduces erythropoiesis [12][13][14][15][16] and hypogonadism is frequently associated with reduced Hct [17]. Both conditions are reversible with androgen replacement treatment [18] or by removing androgen deprivation [16,19].…”

Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: A retrospective chart review

“…This finding agrees with the results of a study by Eri and Tveter. In their study of 50 patients receiving leuprolide therapy for BPH, a mean decline in haemoglobin of 0.8 g/dL at 6 months was observed [10]. Similarly, Weber et al reported a haemoglobin decline of 1.1 g/dL at 6 months in a study of 10 men receiving the GNRHagonist nafarelin for BPH [9].…”

“…More recently, Fonseca et al described a series of 64 patients undergoing orchiectomy for prostate cancer; patients were found to have a statistically significant drop in haemoglobin concentration of 1.2 g/dL on average at 90 days following orchiectomy [8]. Additional reports by Weber et al [9], and Eri and Tveter [10], detail drops in haemoglobin levels with the use of GnRHagonist therapy for benign prostatic hyperplasia (BPH). Based on the available data, it is apparent that testosterone levels influence haemoglobin levelswith a decline in testosterone levels, haemoglobin levels predictably fall.…”

Effects of Radiation and Total Androgen Blockade on Serum Hemoglobin, Testosterone, and Erythropoietin in Patients with Localized Prostate Cancer

“…effects on serum testosterone and hemoglobin 1,[7][8][9][10] . Recent studies have confirmed a decline in serum hemoglobin attributable to these newer approaches to tab-and also a variety of other side effects, including metabolic disorders, cardiovascular disease, hot flashes, sexual dysfunction, depressed mood, muscle weakness, and osteoporosis 2,7,[11][12][13][14][15][16][17] .…”